ClinicalTrials.gg
RecruitingNCT07413341in vivo CAR-TUpdated Oct 19, 2026

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

A Phase 1 interventional study of TI-0032-III injection in Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS) and Systemic Sclerosis (SSc), sponsored by Therorna. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Therorna · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
207th of 245
12 · median 36
Started
2026
with 55 others
Phase 1
109 of 266
85 open now
Primary completion
2027-05
later than 95 of 190 live
Registered
226th of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 207th largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 109 in phase 1, reaches primary completion later than 95 of the 190 other live ones, and was the 226th registered.

Lupus Erythematosus, Systemic

1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular RNA encoding the CD19 chimeric antigen receptor (CAR), which is a therapeutic biological product. It is clinically intended for the treatment of various relapsed and refractory B cell-related autoimmune diseases, such as systemic lupus erythematosus, sjögren's syndrome, systemic sclerosis, idiopathic inflammatory myositis, and antiphospholipid syndrome.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)
  • Sjogren's Syndrome (SS)
  • Systemic Sclerosis (SSc)
  • Inflammatory Myopathy
  • ANCA Associated Systemic Vasculitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Understand trial procedures and methods, voluntarily sign the form .
  • Age ranges from 18 to 65 years old (including threshold), regardless of gender.
  • Positive expression of CD19 on peripheral blood B cells determined by flow cytometry.
  • Bone marrow function: ≥ 1.5 × 10\^9/L, lymphocyte count ≥ 0.8 × 10\^9/L, ≥ 90 g/L, ≥ 100 × 10\^9/L. Blood transfusion and growth factors must not be used within 14 days prior to screening to meet the above requirements.
  • Coagulation function: or activated partial thromboplastin time ≤ 1.5× (ULN).
  • Cardiopulmonary function: ≥ 50% on echocardiography; for lung function, dyspnea ≤Grade 1 of the version 5.0 standards when breathing room air, and pulse oximetry ≥ 92%.
  • Liver function: ≤ 1.5 × ULN, aspartate aminotransferase ≤ 1.5 × ULN, total ≤ 1.5 × ULN (total bilirubin at least ≤ 3.0 mg/dL in patients with Gilbert syndrome).
  • Renal function: (by Cockcroft-Gault formula) ≥ 50 mL/min.
  • Criteria for SLE:

    1. Meet the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) classification criteria for SLE;
    2. SLEDAI-2000 score > 6 in the moderate to severe active phase of the disease;
    3. And have at least one British Isles Lupus Assessment Group (BILAG-2004) grade A (severe manifestation) or two grade B (moderate manifestation) organ scores, or both.
    4. Ineffective conventional treatment or relapse of disease activity after remission. Definition of routine treatment: Use of (Above 1 mg/kg/d) and cyclophosphamide, and any of the following immunomodulatory drugs for more than 6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics such as rituximab, belimumab, and telitacicept.
  • Criteria for Sjögren's syndrome:

    1. Meet the 2002 AECG criteria for primary Sjögren's syndrome or the 2016 ACR/EULAR classification criteria;
    2. Disease activity ESSDAI ≥ 6;
    3. Anti-SSA/Ro antibody positive;
    4. Definition of relapse/: disease activity that is ineffective to conventional treatment for more than 6 months or recurs after response. Definition of conventional treatment is use of glucocorticoids and cyclophosphamide, and any of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, and telitacicept.
  • Criteria for systemic sclerosis:

    1. Meet the 2013 ACR classification criteria for systemic sclerosis and meet diffuse manifestations;
    2. Combined interstitial pneumonia: interstitial changes with ground-glass exudate detected by chest high-resolution computed tomography (HRCT);

      Needs to be met c. or d.:

    3. Ineffective conventional treatment or relapse of disease activity after remission. Definition of routine treatment: Use of glucocorticoids (Above 0.5 mg/kg/d) and cyclophosphamide, and any of the following immunomodulatory drugs for more than 6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics such as rituximab and belimumab.
    4. Meet the definition of progression: 1) Definition of skin progression: mRSS increases b > 25%; 2) Definition of lung disease progression: FVC decreased by 10%, or FVC decreased by 5% and DLCO decreased by 15%.
  • Criteria for inflammatory myopathy:

    1. The classification criteria for inflammatory myopathy comply with the 2017 EULAR/ACR (including DM, PM, ASS and NM);
    2. For patients with muscle involvement, the MMT-8 score is less than 142 and abnormalities are found in at least two of the following five core measures (PhGA, PtGA, or extramuscular disease activity score ≥ 2 points; total HAQ score ≥ 0.25; muscle enzyme level is 1.5 times upper limit of normal);
    3. Myositis antibody positive;

      Needs to be met d. or e.:

    4. Definition of relapse/refractory: Failure of conventional treatment or relapse of disease activity after response. Definition of conventional treatment: Use of glucocorticoids (greater than 1 mg/kg/d) and cyclophosphamide, and any of the following immunomodulatory drugs for more than 6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics such as rituximab and belimumab.
    5. Meet the definition of progression: Interstitial pneumonia progresses rapidly over a short period of time.
  • Criteria for ANCA-associated vasculitis:

    1. Meet the diagnostic criteria for ANCA-associated vasculitis in the 2022 ACR/EULAR, including microscopic polyangiitis, granulomatous polyangiitis, eosinophilic granulomatosis with polyangiitis;
    2. ANCA-related antibody positive (MPO-ANCA or PR3-ANCA positive);
    3. Birmingham Vasculitis Activity Scale (BVAS) ≥ 15 points (out of a total of 63 points), indicating activity of vasculitis;
    4. Must have at least one major item, at least three minor items, or at least two renal items, hematuria and proteinuria, in the BVAS assessment;
    5. Definition of relapse/refractory: Failure of conventional treatment or relapse of disease activity after response. Definition of conventional treatment: Use of glucocorticoids (greater than 1 mg/kg/d) and cyclophosphamide, and any of the following immunomodulatory drugs for more than 6 months: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics such as rituximab and belimumab.

Exclusion criteria

Exclusion Criteria:

  • Prohibited medications and treatments:

    • Any RNA-LNP products or other LNP drugs received within the past two years.
    • Received intravenous gamma immunoglobulin within 24 weeks prior to screening.
    • Received plasmapheresis therapy within 12 weeks prior to screening.
    • Subjects who have not fully recovered from surgery within 4 weeks prior to screening.
    • Epilepsy or use of psychotropic or sedative drugs during the screening period (except medications for sleeping).
    • Received any live or within 12 weeks prior to screening, or requiring vaccination at any time during clinical trial treatment.
    • Participated in clinical trial of other drugs or medical devices within 12 weeks prior to screening (except for those whose screening failed).
  • Concomitant diseases or clinical condition:

    • History of lupus nephropathy requiring hemodialysis or treatment with high-dose (> 100 mg/d prednisone or equivalent) within 90 days prior to baseline.
    • Epilepsy or use of psychotropic or sedative drugs during the screening period (except medications for sleeping).
    • Received any live or live attenuated vaccine within 12 weeks prior to screening, or requiring vaccination at any time during clinical trial treatment.
    • Participated in clinical trial of other drugs or medical devices within 12 weeks prior to screening (except for screen failures).
    • Have active central nervous system lupus, including meningitis aseptic, cerebral vasculitis, demyelinating syndrome, myelopathy, acute demented, psychosis, acute inflammatory demyelinating polyradiculoneuropathy, mononeuropathy (single/multiple), cranial neuropathy, plexopathy, status epilepticus or cerebellar ataxia.
    • Presence of other systemic inflammations such as, but not limited to, rheumatoid arthritis, juvenile chronic arthritis, spondyloarthritis, Crohn's disease, ulcerative colitis, or psoriatic arthritis within 12 weeks prior to screening (except for those with secondary Sjögren's syndrome, who should not be excluded).
    • Subjects who have Grade III or above congestive heart failure ( grade), unstable angina or myocardial infarction, poorly controlled hypertension (hypertension is diagnosed as Grade 2 or above, risk factor stratified as high-risk, systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg when taking one or two antihypertensive drugs, cerebrovascular accidents, or arrhythmias requiring treatment within 6 months prior to screening.
    • Presence of active or uncontrolled infection requiring treatment; or have known or suspected ongoing, chronic, or recurrent infectious diseases (including but not limited to opportunistic infections such as pulmonary tuberculosis, atypical mycobacterosis, listeriosis or aspergillosis, , or , etc.).
    • Subjects with suspected allergy to TI-0032-III or similar drugs or a history of severe allergy or reactions.
    • History of thyrotoxicosis, including but not limited to diffuse toxic goitre, multinodular toxic goiter, thyroid autonomic high-function adenoma, and subacute thyroiditis, or thyroid color ultrasound suggests thyroid nodules TI-RADS classification as category 4 or 5.
    • Previous history of splenectomy or loss of spleen function after splenic infarction or splenic vein thrombosis leading to direct vascular injury; or major surgery within 2 months prior to screening; or have planned surgery before the end of the trial.
    • Have other serious/severe acute or chronic mental illness, including recent (within the past 1 year) or current suicidal ideation or behavior; or a history of alcohol, drug, or chemical abuse within 1 year prior to screening.
    • History of major organ transplant (e.g., heart, lung, liver, kidney) or bone marrow/hematopoietic stem cell transplantation.
    • History of , regardless of evidence of local recurrence or and regardless of treatment; or accompanied by a history of other major diseases, such as liver disease under treatment, including but not limited to acute or chronic hepatitis, liver cirrhosis or liver failure, etc.
    • HIV positive, or active hepatitis B virus test positive (HBsAg positive, HBV-DNA ≥ 200 copies/mL is required (conversion is required if HBV-DNA is in IU/mL)), or anti-HCV antibody positive and HCV-RNA positive.
    • Women who plan to become pregnant or are pregnant or breastfeeding; or blood pregnancy test positive during screening; or unable to take effective measures within 12 months after the last infusion of drug; or planned sperm/egg donation within 12 months after the last dose of the investigational drug.
    • Other abnormal laboratory tests or imaging tests judged by the investigator or considered unsuitable for clinical the trial for other reasons.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    TI-0032-III injection

    In vivo CD19-targeted Chimeric Antigen Receptor (CAR) T Cell Therapy

    Biological: TI-0032-III injection

Interventions

  • BiologicalTI-0032-III injection

    Multiple doses of TI-0032-III injection will be infused

06

What researchers measure

Primary outcomes

  1. Safety outcomes

    Safety assessments are conducted using the NCI-CTCAE version 5.0 standards

    Time frame: From first dose of TI-0032-III injection until 12 months

Secondary outcomes

  1. Efficacy outcome for systemic lupus erythematosus

    Systemic lupus erythematosus-SLE Responder Index-4 (SRI-4) response expressing in percentages

    Time frame: From first dose of TI-0032-III injection until 3 months

  2. Efficacy outcome for Sjögren's syndrome

    Sjögren's syndrome -Sjögren's Tool for Assessing Response (STAR) presented as accumulated scores

    Time frame: From first dose of TI-0032-III injection until 3 months

  3. Efficacy outcome for systemic sclerosis

    Systemic sclerosis-Composite Response Index in Systemic Sclerosis (CRISS) score

    Time frame: From first dose of TI-0032-III injection until 3 months

  4. Efficacy outcome for inflammatory myopathy

    Inflammatory myopathy-Total Improvement Score (TIS)

    Time frame: From first dose of TI-0032-III injection until 3 months

  5. Efficacy outcome for ANCA-associated vasculitis

    ANCA-associated vasculitis-BVAS score

    Time frame: From first dose of TI-0032-III injection until 3 months

Other outcomes

  1. Exploratory PK outcomes

    Rate of CAR expression in peripheral blood cells

    Time frame: From first dose of TI-0032-III injection until 3 months

  2. Exploratory PK outcomes

    Quantification of circular RNA in peripheral blood

    Time frame: From first dose of TI-0032-III injection until 3 months

  3. Exploratory PD outcome

    Percentage and count of B cells in the peripheral blood

    Time frame: From first dose of TI-0032-III injection until 12 months

  4. Exploratory PD outcome

    Rate of B cell subsets (naïve B cells, memory B cells, transitional B cells, plasma cells and immature B cells) in the peripheral blood

    Time frame: From first dose of TI-0032-III injection until 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 15 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 15 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion May 2026 → May 2027 and completion Jan 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 17, 2026
StartActual
Jan 22, 2026
Primary completionEst.
May 1, 2027was May 2026
CompletionEst.
May 30, 2027was Jan 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 1, 2026→May 1, 2027
Oct 19, 2026
Study completion
Jan 30, 2027→May 30, 2027
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion May 1, 2026→May 1, 2027
    Study completion Jan 30, 2027→May 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07413341
Lead sponsor
Therorna
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Jan 22, 2026
Primary completion
May 1, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Xiao bing Wang, PhD
Contact
gale820907@163.com
021-81886999
Hu ji Xu, PhD
Contact
Hu ji Xu
principal investigator · Shanghai Changzheng Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion